Unique circulating microRNA profiles in epidemic Kaposi's sarcoma.
Biomarker
Blood
Circulating microRNA
Kaposi's sarcoma
Serum
microRNA
Journal
Non-coding RNA research
ISSN: 2468-0540
Titre abrégé: Noncoding RNA Res
Pays: Netherlands
ID NLM: 101688191
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
19
10
2021
revised:
24
01
2022
accepted:
12
02
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
17
5
2022
Statut:
epublish
Résumé
Human herpesvirus 8 (HHV-8) causes Kaposi's sarcoma (KS). Kaposi sarcoma in HIV/AIDS patients is referred to as epidemic KS and is the most common HIV-related malignancy worldwide. The lack of a diagnostic assay to detect latent and early-stage disease has increased disease morbidity and mortality. Serum miRNAs have previously been used as potential biomarkers of normal physiology and disease. In the current study, we profiled unique serum miRNAs in patients with epidemic KS to generate baseline data to aid in developing a miRNA-based noninvasive biomarker assay for epidemic KS. This was a comparative cross-sectional study involving 27 patients with epidemic KS and 27 HIV-positive adults with no prior diagnosis or clinical manifestation of KS. DNA and RNA were isolated from blood and serum collected from study participants. Nested PCR for circulating HHV-8 DNA was performed on the isolated DNA, whereas miRNA library preparation and sequencing for circulating miRNA were performed on the RNA samples. The miRge2 pipeline and EdgeR were used to analyse the sequencing data. Fifteen out of the 27 epidemic KS-positive subjects (55.6%) tested positive for HHV-8 DNA, whereas only 3 (11.1%) out of the 27 HIV-positive, KS-negative subjects tested positive for HHV-8 DNA. Additionally, we found a unique miRNA expression signature in 49 circulating miRNAs in epidemic KS subjects compared to subjects with no epidemic KS, with 41 miRNAs upregulated and 8 miRNAs downregulated. Subjects with latent KS infection had a differential upregulation of circulating miR-193a compared to HIV-positive, KS-negative subjects for whom circulating HHV-8 DNA was not detected. Further analysis of serum from epidemic KS patients revealed a miRNA signature according to KS tumor status and time since first HIV diagnosis. This study reveals unique circulating miRNA profiles in the serum of patients with epidemic KS versus HIV-infected subjects with no KS, as well as in subjects with latent KS. Many of the dysregulated miRNAs in epidemic KS patients were previously reported to have crucial roles in KS infection and latency, highlighting their promising roles as potential biomarkers of latent or active KS infection.
Sections du résumé
Background
UNASSIGNED
Human herpesvirus 8 (HHV-8) causes Kaposi's sarcoma (KS). Kaposi sarcoma in HIV/AIDS patients is referred to as epidemic KS and is the most common HIV-related malignancy worldwide. The lack of a diagnostic assay to detect latent and early-stage disease has increased disease morbidity and mortality. Serum miRNAs have previously been used as potential biomarkers of normal physiology and disease. In the current study, we profiled unique serum miRNAs in patients with epidemic KS to generate baseline data to aid in developing a miRNA-based noninvasive biomarker assay for epidemic KS.
Methods
UNASSIGNED
This was a comparative cross-sectional study involving 27 patients with epidemic KS and 27 HIV-positive adults with no prior diagnosis or clinical manifestation of KS. DNA and RNA were isolated from blood and serum collected from study participants. Nested PCR for circulating HHV-8 DNA was performed on the isolated DNA, whereas miRNA library preparation and sequencing for circulating miRNA were performed on the RNA samples. The miRge2 pipeline and EdgeR were used to analyse the sequencing data.
Results
UNASSIGNED
Fifteen out of the 27 epidemic KS-positive subjects (55.6%) tested positive for HHV-8 DNA, whereas only 3 (11.1%) out of the 27 HIV-positive, KS-negative subjects tested positive for HHV-8 DNA. Additionally, we found a unique miRNA expression signature in 49 circulating miRNAs in epidemic KS subjects compared to subjects with no epidemic KS, with 41 miRNAs upregulated and 8 miRNAs downregulated. Subjects with latent KS infection had a differential upregulation of circulating miR-193a compared to HIV-positive, KS-negative subjects for whom circulating HHV-8 DNA was not detected. Further analysis of serum from epidemic KS patients revealed a miRNA signature according to KS tumor status and time since first HIV diagnosis.
Conclusions
UNASSIGNED
This study reveals unique circulating miRNA profiles in the serum of patients with epidemic KS versus HIV-infected subjects with no KS, as well as in subjects with latent KS. Many of the dysregulated miRNAs in epidemic KS patients were previously reported to have crucial roles in KS infection and latency, highlighting their promising roles as potential biomarkers of latent or active KS infection.
Identifiants
pubmed: 35570854
doi: 10.1016/j.ncrna.2022.02.002
pii: S2468-0540(22)00007-5
pmc: PMC9065625
doi:
Types de publication
Journal Article
Langues
eng
Pagination
114-122Subventions
Organisme : FIC NIH HHS
ID : D43 TW010132
Pays : United States
Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Genomics Proteomics. 2009 Sep-Oct;6(5):281-95
pubmed: 19996134
N Engl J Med. 2009 Oct 8;361(15):1437-47
pubmed: 19812400
Tumour Biol. 2015 Jan;36(1):437-46
pubmed: 25266797
Nat Cell Biol. 2010 May;12(5):513-9
pubmed: 20418869
Semin Diagn Pathol. 2017 Jul;34(4):371-376
pubmed: 28502522
Lab Invest. 2019 Apr;99(4):452-469
pubmed: 30542067
Front Microbiol. 2018 Dec 21;9:3185
pubmed: 30619232
Adv Virol. 2011;2011:
pubmed: 21625290
Sao Paulo Med J. 2015 Apr 14;134(3):187-92
pubmed: 25885486
Oncogene. 2010 Mar 25;29(12):1835-44
pubmed: 20023696
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):295-301
pubmed: 26452066
Virol J. 2017 Apr 7;14(1):71
pubmed: 28388926
Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4
pubmed: 16381832
J Acquir Immune Defic Syndr. 2012 Jun 1;60(2):150-7
pubmed: 22395672
J Antimicrob Chemother. 2003 May;51(5):1095-8
pubmed: 12668573
Arch Virol. 2017 Nov;162(11):3293-3303
pubmed: 28707270
Front Genet. 2013 Jun 28;4:119
pubmed: 23825476
BMC Bioinformatics. 2018 Jul 23;19(1):275
pubmed: 30153801
Cancers (Basel). 2019 Mar 23;11(3):
pubmed: 30909610
J Acquir Immune Defic Syndr. 2017 Apr 15;74(5):548-554
pubmed: 28107226
J Mol Diagn. 2012 Sep;14(5):510-7
pubmed: 22749746
J Cell Sci. 2011 Aug 15;124(Pt 16):2826-36
pubmed: 21807947
J Cell Physiol. 2016 Apr;231(4):829-36
pubmed: 26284581
PLoS Pathog. 2017 Jan 3;13(1):e1006143
pubmed: 28046107
PLoS One. 2016 Sep 09;11(9):e0162574
pubmed: 27611973
PLoS One. 2010 Nov 12;5(11):e13936
pubmed: 21103057
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
J Clin Aesthet Dermatol. 2019 Nov;12(11):23-26
pubmed: 32038753
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
PLoS One. 2014 May 14;9(5):e95920
pubmed: 24828336
Methods. 2013 Jan;59(1):S1-6
pubmed: 23036329
BMC Cancer. 2016 Feb 06;16:65
pubmed: 26852390
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Clin Microbiol Rev. 2002 Jul;15(3):439-64
pubmed: 12097251
Gynecol Oncol. 2009 Aug;114(2):253-9
pubmed: 19446316
Viruses. 2014 Nov 21;6(11):4571-80
pubmed: 25421888
Best Pract Res Clin Endocrinol Metab. 2016 Oct;30(5):563-575
pubmed: 27923451
J Exp Clin Cancer Res. 2017 Dec 08;36(1):178
pubmed: 29216925